Hazard ratios (HRs) were adjusted for chemotherapy, trastuzumab, age at diagnosis, N-status, grade, pT-stage and ovarian ablation. Results: During follow-up, 237 recurrences and 182 deaths occurred.
Book Title: Optimal Adjuvant Endocrine Treatment of ER+/HER2+ Breast Cancer Patients by Age at Diagnosis: A Population-based Cohort Study
Author:
Published on 2018 by
ISBN: /
Total Page:
Book Category:
Book is About: Breast Cancer Treatment
Get Optimal Adjuvant Endocrine Treatment of ER+/HER2+ Breast Cancer Patients by Age at Diagnosis: A Population-based Cohort Study eBook

Abstract: Background: Prior randomised controlled trials on adjuvant hormonal therapy included HER2any patients; however, a differential effect of aromatase inhibitors (AIs) versus tamoxifen (TAM) may have been missed in ER+/HER2+ patients that comprise 7–15% of all breast cancer patients. In addition, a woman's hormonal microenvironment may influence sensitivity to TAM and AIs in the adjuvant setting, which changes during menopausal transition, a process that takes years. We studied the efficacy of AIs versus TAM in ER+/HER2+ breast cancer patients grouped by age at diagnosis as a proxy for menopausal status using treatment and outcome data from the nationwide population-based Netherlands Cancer Registry (NCR). Patients and methods: All women diagnosed between 2005 and 2007 with endocrine-treated, Tany Nany M0, ER+/HER2+ breast cancer were identified through the NCR ( n =1155). Patients were divided by age at diagnosis: premenopausal (≤45 years; n =326), perimenopausal (4555 years; n =525). A time-dependent variable, indicating whether AI or TAM was received for \u003e50% of endocrine treatment duration, was applied to subdivide groups by predominant treatment received. Recurrence-free survival (RFS) and overall survival (OS) were assessed using Kaplan–Meier survival estimation and Cox regression. Hazard ratios (HRs) were adjusted for chemotherapy, trastuzumab, age at diagnosis, N-status, grade, pT-stage and ovarian ablation. Results: During follow-up, 237 recurrences and 182 deaths occurred. Perimenopausal women derived significant RFS and OS benefit from AI compared with TAM, HR 0.47 (95% CI 0.25–0.91; P =0.03) and HR 0.37 (95% CI 0.18–0.79; P =0.01), respectively, whereas premenopausal women derived no benefit from AI compared with TAM. Treatment effects differed significantly between these age groups (interaction P =0.03 and P =0.02, respectively). Among postmenopausal women a small but non-significant AI benefit was observed. Conclusion: AI treatment, preferably without any TAM treatment, was associated with the best RFS and OS outcome in ER+/HER2+ perimenopausal breast cancer patients. Highlights: We studied all ER+/HER2+ Dutch breast cancer patients diagnosed between 2005 and 2007. Aromatase inhibitors (AIs) and tamoxifen (TAM) were compared in a time-dependent way. AIs not TAM significantly improve recurrence-free survival (RFS) and overall survival (OS) in perimenopausal women (45–55yearsat diagnosis). 5-year RFS benefit for AI compared with TAM (90% vs. 78%; adjusted HR 0.47; P =0.026). 5-year OS benefit for AI compared with TAM (96% vs. 87%; adjusted HR 0.37; P =0.010).
From the most popular Breast Cancer Treatment Books, Optimal Adjuvant Endocrine Treatment of ER+/HER2+ Breast Cancer Patients by Age at Diagnosis: A Population-based Cohort Study is the one of great book to have. You can get ebook from:
There are so many ebooks about Optimal Adjuvant Endocrine Treatment of ER+/HER2+ Breast Cancer Patients by Age at Diagnosis: A Population-based Cohort Study that are available to have. Thinking of having Optimal Adjuvant Endocrine Treatment of ER+/HER2+ Breast Cancer Patients by Age at Diagnosis: A Population-based Cohort Study ebook? You are in the right place. Get the ebook Optimal Adjuvant Endocrine Treatment of ER+/HER2+ Breast Cancer Patients by Age at Diagnosis: A Population-based Cohort Study by: .

- Book was ranked at 33 by Google Books for Optimal Adjuvant Endocrine Treatment of ER+/HER2+ Breast Cancer Patients by Age at Diagnosis: A Population-based Cohort Study
- Optimal Adjuvant Endocrine Treatment of ER+/HER2+ Breast Cancer Patients by Age at Diagnosis: A Population-based Cohort Study published by since 2018 with ISBNs. The book ISBN 13 Code is and ISBN 10 Code is
- Reading Mode in Text Status is false and Reading Mode in Image Status is false
- The book has " Pages" is Printed at BOOK under Category
- Rated by Raters and have average rate at ""
- eBook Maturity (Adult Book) status is NOT_MATURE
- eBook written in en
- Book Preview Address: http://books.google.com/books?id=cG_KvQEACAAJ&dq=Breast+Cancer+Treatment&hl=&cd=352&source=gbs_api
Book Preview

- Server 2: SECURE LINK